{"protocolSection":{"identificationModule":{"nctId":"NCT02262676","orgStudyIdInfo":{"id":"17671"},"organization":{"fullName":"Bayer","class":"INDUSTRY"},"briefTitle":"Observational Study to Assess Sociodemographic and Clinical Features of Patients Treated With Rivaroxaban in Routine Clinical Practice of Hematologists, Cardiologists and Internists of Spain","officialTitle":"Observational and Cross-sectional Study to Assess the Sociodemographic and Clinical Characteristics of Patients Treated With RIVAROXABAN in the Context of Routine Clinical Practice of Spanish Haematologists, Cardiologists and Internists (HEROIC Study)","acronym":"HEROIC"},"statusModule":{"statusVerifiedDate":"2017-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2014-10"},"primaryCompletionDateStruct":{"date":"2015-02","type":"ACTUAL"},"completionDateStruct":{"date":"2015-05","type":"ACTUAL"},"studyFirstSubmitDate":"2014-10-09","studyFirstSubmitQcDate":"2014-10-09","studyFirstPostDateStruct":{"date":"2014-10-13","type":"ESTIMATED"},"lastUpdateSubmitDate":"2017-01-20","lastUpdatePostDateStruct":{"date":"2017-01-23","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bayer","class":"INDUSTRY"},"collaborators":[{"name":"Janssen Research & Development, LLC","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"Depict demographic and clinical features of patients with atrial fibrillation treated with rivaroxaban to prevent stroke and pulmonary embolism in routine clinical practice"},"conditionsModule":{"conditions":["Atrial Fibrillation"],"keywords":["Stroke prevention on Atrial Fibrillation","Prevention and Control","Stroke"]},"designModule":{"studyType":"OBSERVATIONAL","designInfo":{"observationalModel":"COHORT","timePerspective":"CROSS_SECTIONAL"},"enrollmentInfo":{"count":2251,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Rivaroxaban","description":"Patients with Atrial fibrillation treated with Rivaroxaban","interventionNames":["Drug: Rivaroxaban (Xarelto, BAY59-7939)"]}],"interventions":[{"type":"DRUG","name":"Rivaroxaban (Xarelto, BAY59-7939)","description":"Patients treated by Physicians under approved local prescriptions","armGroupLabels":["Rivaroxaban"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Demographic Data","timeFrame":"At recruitment visit"},{"measure":"Medical History","timeFrame":"At recruitment visit"}],"secondaryOutcomes":[{"measure":"Assess regional differences among the different Spanish autonomous communities on the management of patients with rivaroxaban treatment during the routine clinical practice","description":"By use of Informe de Posicionamiento Terapéutico (Spanish Questionnaire)","timeFrame":"At recruitment visit"},{"measure":"Adherence to rivaroxaban treatment","description":"By use of Morisky-Green questionnaire","timeFrame":"At recruitment visit"},{"measure":"Assess the satisfaction of rivaroxaban treatment","description":"By use of Anti-Clot Treatment Scale (ACTS) questionnaire","timeFrame":"At recruitment visit"},{"measure":"Assess the quality of life in patients","description":"By use of Short-Form 12 Health Survey,version 2 (SF12v2) questionnaire","timeFrame":"At recruitment visit"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients ≥ 18 years\n* Patients with atrial fibrillation\n* Patients in treatment with rivaroxaban for stroke prevention in atrial fibrillation at least 3 months previous to inclusion period in study\n\nExclusion Criteria:\n\n* Patients in treatment after start of study\n* Patients treated with other anticoagulant treatment","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Patients taking rivaroxaban for stroke prevention in atrial fibrillation attending consults of hematology, cardiology and internal medicine","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Bayer Study Director","affiliation":"Bayer","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Many Locations","country":"Spain"}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"}],"ancestors":[{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"},{"id":"T4202","name":"Oculocerebral Syndrome With Hypopigmentation","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069552","term":"Rivaroxaban"}],"ancestors":[{"id":"D000065427","term":"Factor Xa Inhibitors"},{"id":"D000000991","term":"Antithrombins"},{"id":"D000015842","term":"Serine Proteinase Inhibitors"},{"id":"D000011480","term":"Protease Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000000925","term":"Anticoagulants"}],"browseLeaves":[{"id":"M463","name":"Rivaroxaban","asFound":"Weight loss","relevance":"HIGH"},{"id":"M30203","name":"Factor Xa Inhibitors","relevance":"LOW"},{"id":"M3997","name":"Antithrombins","relevance":"LOW"},{"id":"M3996","name":"Antithrombin III","relevance":"LOW"},{"id":"M14033","name":"Protease Inhibitors","relevance":"LOW"},{"id":"M18081","name":"Serine Proteinase Inhibitors","relevance":"LOW"},{"id":"M19299","name":"HIV Protease Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M3934","name":"Anticoagulants","relevance":"LOW"},{"id":"T18","name":"Serine","relevance":"LOW"}],"browseBranches":[{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"AA","name":"Amino Acids"}]}},"hasResults":false}